Mylan gets FDA approval for generic Neurontin
Feb. 28, 2011
Mylan Inc. said Monday its Matrix Laboratories unit received Food and Drug Administration approval to market a generic version of Pfizer Inc.'s drug Neurontin.
Neurontin was originally approved as a treatment for seizures and more recently cleared for pain caused by shingles. The generic name for the drug is gabapentin.
Mylan received approval to market 100-milligram, 300-milligram, and 400-milligram doses of the capsules. The company said the drug had $300 million in sales for the 12-month period ending Dec. 31, according to IMS Health.
Mylan plans to launch the generic version immediately.
Shares of Mylan rose 4 cents to $22.65 in afternoon trading.